Similar articles

• Botulinum toxin should be first-line treatment for poststroke spasticity.

  Sheean G. Sheean G. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):359. doi: 10.1136/jnnp.2008.164889. J Neurol Neurosurg Psychiatry. 2009. PMID: 19289475 No abstract available.
• Drug treatments for spasticity.

  Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, Quentin V, Marque P, Parratte B, Pellas F, Rousseaux M, Trocello JM, Uzzan M, Dumarcet N; Agence française de sécurité sanitaire des produits de santé. Yelnik AP, et al. Ann Phys Rehabil Med. 2009 Dec;52(10):746-56. doi: 10.1016/j.rehab.2009.09.005. Epub 2009 Nov 4. Ann Phys Rehabil Med. 2009. PMID: 19892619 No abstract available.
• The management of focal spasticity.

  Jozefczyk PB. Jozefczyk PB. Clin Neuropharmacol. 2002 May-Jun;25(3):158-73. doi: 10.1097/00002826-200205000-00006. Clin Neuropharmacol. 2002. PMID: 12023570 Review. No abstract available.
• Principles of pharmaceutical management of spastic hypertonia.

  Elovic E. Elovic E. Phys Med Rehabil Clin N Am. 2001 Nov;12(4):793-816, vii. Phys Med Rehabil Clin N Am. 2001. PMID: 11727721 Review.
• [Spasticity. Physical therapy, preventive measures and treatment].

  Gay S, Egon G. Gay S, et al. Ann Fr Anesth Reanim. 2005 Jun;24(6):663-6. doi: 10.1016/j.annfar.2005.03.011. Ann Fr Anesth Reanim. 2005. PMID: 15950113 Review. French.